Illumisoft Lighting Corp. · TSXV:UVC
Illumisoft Lighting — Investor Presentation (September 2026)
29 slides from Illumisoft Lighting's investor presentation, September 2026
Slide 1: Investor Presentation
light INVESTOR PRESENTATION TSX-V : UVC OTCQB : FUVCF September 2026
Slide 2: Legal Notice: Important disclosures
LEGAL NOTICE Important disclosures. FORWARD-LOOKING INFORMATION INDUSTRY AND MARKET DATA This presentation contains "forward-looking information" within the meaning of applicable Canadian securities laws and Market data, statistics, and forecasts cited herein are derived from third-party sources, in
Slide 3: The Missing Layer
THE MISSING LAYER We solved fire. We solved water. We never solved air. Every other shared risk got permanent infrastructure. Air is still improvised. FIRE WATER AIRBORNE PATHOGENS Building codes. Municipal treatment. Continuous pathogen reduction Automatic sprinklers. Sanitation systems. built into
Slide 4: The People Behind the Opportunity
THE PEOPLE BEHIND THE OPPORTUNITY These are not just buildings. They are where life happens. SCHOOLS SENIOR CARE AVIATION CRUISES Your child Your grandparents Your family Your next holiday in a classroom. in senior care. on a plane. on a cruise ship. The ambition: make protection part of the places
Slide 5: The Global Healthcare Burden
THE GLOBAL HEALTHCARE BURDEN People go into hospital to get well. Around 1 in 10 136M patients is affected by a healthcare-associated infection. healthcare-associated antibiotic-resistant infections estimated worldwide each year. Protection should not end at the hospital door. When an infection resi
Slide 6: The Global Economic Cost
THE GLOBAL ECONOMIC COST The cost does not stop at the bedside. US$412B US$443B US$855B Annual treatment expenses Annual productivity losses If nothing changes For resistant bacterial infections. From illness and mortality. Treatment and productivity, combined. Modeled to 2035 Modeled to 2035 Modele
Slide 7: The Cost of Infection
THE COST OF INFECTION A major economic and human cost. Healthcare-acquired infections are a significant, preventable burden on Canada's healthcare system. 473,590 33,151 C$29.3B Healthcare-acquired Associated deaths a Estimated annual economic burden. infections a year. year. C$9.47B treatment costs
Slide 8: The Prevention Case
THE PREVENTION CASE The money goes to treatment. The leverage is in prevention. AFTER INFECTION BEFORE EXPOSURE Help the patient recover. Reduce pathogens in shared air. Add engineered UV to ventilation, filtration and other infection Diagnosis. Appropriate treatment. Responsible antibiotic use. con
Slide 9: Why Now
WHY NOW The pressure to act is building. Standards, procurement, liability and preparedness, 2024 to 2026. 1 Indoor air is a health crisis Indoor transmission drives the burden, and clean-air expectations have moved. HEALTH CRISIS 2 Standards are tightening WHO and CDC raised clean-air targets. ASHR
Slide 10: Global Competitive Position
GLOBAL COMPETITIVE POSITION Built for global leadership. SaniLume SaniLux ECOWing COMMERCIAL UPPER ROOM GUV FAR-UVC IN DEVELOPMENT COMMERCIAL LIGHTING ACTIVE COMING SOON REVENUE PRODUCING Best at Leeds 70x output 34 of 50 Best UV device tested in the Leeds chamber. Against the stated excimer benchma
Slide 11: Conviction Behind the Mission
CONVICTION BEHIND THE MISSION Partners in the mission. Invested in its future. Chris Anderson Rob Reid RESILIENCE RESERVE / TED RESILIENCE RESERVE / RHAPSODY / STRATEGIC ADVISOR "Far-UVC is the most promising biosecurity technology I have "This could greatly enhance social resilience at all levels o
Slide 12: A Proven Scientific Foundation
A PROVEN SCIENTIFIC FOUNDATION A century of science. A new level of engineering. 1937 1994 2022 School experiments CDC guidance SaniLume testing Upper-room UV was being studied in classrooms. UVGI appeared in healthcare TB-control guidance. The University of Leeds tested Illumisoft's device. CATEGOR
Slide 13: SaniLume Today
SANILUME TODAY Treat the air while the room is in use. 254 nm UPPER-ROOM GUV 1 Position UV is mounted above head height, so occupants never meet the beam. 2 Circulate Fans draw room air continuously through the germicidal field. CFD aerosol modelling 3 Repeat Pathogens spread through a classroom wit
Slide 14: SaniLume / Independent Testing
SANILUME / INDEPENDENT TESTING Best in the Leeds chamber. " 99.7% The best performing UV device that has been tested in the aerobiology chamber at the University of Leeds to date. P. aeruginosa reduction in laboratory chamber testing. Dr. Louise Fletcher University of Leeds / August 2022 LEEDS CHAMB
Slide 15: Commercial Traction
COMMERCIAL TRACTION A hospital program with meaningful scale. STILL CONDITIONAL Winnipeg 1,000 1,500 Tertiary facility CHAIR sign-off $200k funder deposit Budgeted SaniLume units On-site audit BC + Fraser Health across two hospital programs. 500 Partnered study Final scope, capped at budget 1 2 3 4
Slide 16: SaniLux
SANILUX A new source. A broader ambition. 216 nm Proprietary nanoengineered Far-UVC. Core IP owned by Illumisoft. IN DEVELOPMENT / OWNED IP 254 nm SaniLume, upper-room GUV 216 nm SaniLux, Far-UVC in development Treat circulating air above occupants. Shipping today. Develop continuous disinfection fo
Slide 17: SaniLux / Company-Reported Advantages
SANILUX / COMPANY-REPORTED ADVANTAGES Designed to move beyond excimer. 70x 10,000+ Owned Power output Hours of product life Core Far-UVC IP Against the stated excimer benchmark. Company-stated development target. No third-party source licensing dependency claimed. METRIC CONVENTIONAL COMPARATOR IN S
Slide 18: Capgemini Partnership / Global Scale
CAPGEMINI PARTNERSHIP / GLOBAL SCALE From breakthrough science to products built for real life. Delivered through frog and Synapse, part of Capgemini. EUR 22.5B 417,600 50+ Global revenue People worldwide Countries Full year 2025 As at 30 June 2026 Global operations 1 2 3 Design for use Engineer to
Slide 19: Independent Category Assessment
INDEPENDENT CATEGORY ASSESSMENT Blueprint makes the infrastructure case. " Far-UVC represents one of the highest-leverage funding opportunities in airborne disease and pandemic prevention that we are aware of. Blueprint Biosecurity / Blueprint for Far-UVC, 2025 10:1 30 to 290x ROI cited for ASHRAE 2
Slide 20: ECOWing / The Commercial Foundation
ECOWING / THE COMMERCIAL FOUNDATION 34 of the top 50. In one portfolio. 167 lm/W of DLC-listed efficiency, engineered and manufactured in Ottawa. The revenue base and the warm channel into both UV platforms. REVENUE PRODUCING 167 lm/W 60 to 75% 5 min 50,000 h 17 40 to 55% Peak efficacy Energy saving
Slide 21: The Addressable Opportunity
THE ADDRESSABLE OPPORTUNITY Start where the need is clear. Expand into everyday life. $9.7B $5.25B ~$8B SaniLume SaniLux ECOWing Hospital serviceable addressable Phase 1: hospitals and aviation. North American LED retrofit market. market. Phase 2 schools and commercial, $35B+. 30,000 230K x 12 units
Slide 22: Go to Market and Commercial Model
GO TO MARKET AND COMMERCIAL MODEL From Canadian execution to global scale. 1 2 3 ACTIVE QUEUED SCALE Canada first International expansion SaniLux commercialization 10 to 15K 50K 216 nm Units/year capacity reported for Ottawa. Units/year capacity target for the next phase. Own the Far-UVC platform an
Slide 23: Institutional Context
INSTITUTIONAL CONTEXT Different relationships prove different things. REGULATORY R&D PARTNER REAL ESTATE REAL ESTATE REAL ESTATE FEDERAL HOSPITAL PILOT STANDARDS BODY RANKINGS COALITION BOARD CONNECT INDUSTRY AWARD CATEGORY ORGANIZATIONS NAMED IN SOURCE MEANING RETAINED Regulation / standards Health
Slide 24: Leadership and Adoption
LEADERSHIP AND ADOPTION Science, commercialization and adoption. Ehsan Agahi Dr. Michael Johnson Ali Pickett CHIEF EXECUTIVE OFFICER CHIEF TECHNOLOGY OFFICER CHIEF FINANCIAL OFFICER Physics PhD, ASU. Former Motorola semiconductor. Architect of 15+ yrs financial leadership. Managed $8B+ in assets. TS
Slide 25: Strategic Advisor / Healthcare Adoption
STRATEGIC ADVISOR / HEALTHCARE ADOPTION Great technology must also get adopted. Former White House HIS ROLE AT ILLUMISOFT Chief Healthcare Economist Build the economic case and 2025 to 2026 help navigate procurement, reimbursement and institutional adoption. Distinguished Research Professor, Arizona
Slide 26: The Investment Opportunity
THE INVESTMENT OPPORTUNITY Small-cap entry. Global infrastructure ambition. ILLUMISOFT / TRADING TODAY R-ZERO / HISTORICAL FINANCING ~C$51M ~C$735M Indicative basic market capitalization Estimated 2023 post-money valuation 46,173,389 shares x a C$1.11 reference price, early September 2026. The US$52
Slide 27: Capital Structure
CAPITAL STRUCTURE Capitalization and capital deployment. SHARES OUTSTANDING USE OF PROCEEDS Issued common shares 46,173,389 Manufacturing and inventory scale ~35% Options 3,540,000 Sales and channel expansion, CA and US ~30% Finder warrants 425,390 SaniLux R&D and prototype completion ~20% FULLY DIL
Slide 28: Investment Thesis
INVESTMENT THESIS Six reasons. Why Illumisoft. 1 2 3 Standards 1,994 eACH 70x Structural demand Validated performance An unpriced option CSA Z8000:24 and Z317.12:25 put engineered air disinfection 1,994 equivalent air changes per hour against P. aeruginosa, 70x the stated excimer benchmark, IP owned
Slide 29: Safer air. Better health. Better future.
Safer air. Better health. Better future. WEB CONTACT REGISTERED LISTINGS illumisoft.com info@illumisoft.com Ottawa, Canada TSX-V : UVC | OTCQB : FUVCF
Illumisoft Lighting — Investor Presentation (September 2026) on 6ix